Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
International Journal of Medicinal Mushrooms
Facteur d'impact: 1.423 Facteur d'impact sur 5 ans: 1.525 SJR: 0.431 SNIP: 0.716 CiteScore™: 2.6

ISSN Imprimer: 1521-9437
ISSN En ligne: 1940-4344

Volumes:
Volume 22, 2020 Volume 21, 2019 Volume 20, 2018 Volume 19, 2017 Volume 18, 2016 Volume 17, 2015 Volume 16, 2014 Volume 15, 2013 Volume 14, 2012 Volume 13, 2011 Volume 12, 2010 Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000 Volume 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushr.v6.i1.30
8 pages

A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) Extract in Patients with Type II Diabetes Mellitus

Yihuai Gao
Institute of Food, Nutrition and Human Health, Massey University; Landcare Research, Private Bag 92170, Auckland, New Zealand
Jin Lan
Institute of Human Nutrition and Department of Biochemistry, Qingdao Medical College, Qingdao University, China
Xihu Dai
Department of Internal Medicine, Fuzhou General Hospital of Nanjing Military Region of the Peoples' Liberation Army, Fuzhou, R.P. China
Jingxian Ye
Department of Integrated Medicine. Hospital of Fujian University of Traditional Chinese Medicine, Fuzhou, R.P. China
Shufeng Zhou
Division of Pharmacy, School of Life Sciences, Faculty of Science, Queensland University of Technology, Australia; Department of Pharmacy, Faculty of Science, National University of Singapore; University of South Florida FL 33612, USA

RÉSUMÉ

Animal studies have demonstrated that the polysaccharide fractions of Ganoderma lucidum (Ling Zhi, reishi mushroom) have potential hypoglycemic and hypolipidemic activities. This clinical study aimed to evaluate the efficacy and safety of Ganopoly (polysaccharide fractions extracted from G. lucidum by patented technique) in 71 patients with confirmed type II diabetes mellitus (DM). Eligibility criteria included type II DM of >3 months’ duration for which patients were not receiving insulin; age >18 years; normal vital signs for age and disease state; normal electrocardiogram (ECG); and fasting plasma glucose (FPG) level of 8.9.16.7 mmol/L in sulfonylurea-naive patients or an FPG <10 mmol/L before washout in sulfonylurea-treated patients. Patients were randomly grouped to be given either Ganopoly or placebo orally at 1800 mg three times daily for 12 weeks. Patients underwent 4 weeks of dose adjustment followed by 8 weeks of dose maintenance. Fasting and stimulated glycosylated hemoglobin (HbA1c), plasma glucose, insulin, and C-peptide were monitered at predetermined intervals. Adverse events and hypoglycemic episodes were recorded. The treatment of Ganopoly significantly decreased the mean HbA1c from 8.4 at baseline to 7.6% at 12 weeks. Significant changes in mean FPG and PPG levels at the last visit paralleled the changes in mean HbA1c levels. At baseline, the mean FPG and PPG values in patients treated with Ganopoly were 12.0 and 13.6 mmol/L, respectively. At week 12, mean PPG values had decreased to 11.8 mmol/L. However, these parameters did not change or slightly increased in patients receiving placebo. The between-group difference in PPG levels at week 12 was significant (p < 0.05). Changes in fasting insulin, 2-hour post-prandial insulin, fasting C-peptide, and 2-hour post-prandial C-peptide were consistent, with the between-group differences in these end points being significant at the last visit. Overall, Ganopoly was well tolerated. This study demonstrated that Ganopoly was efficacious and safe in lowering blood glucose concentrations.


Articles with similar content:

Aqueous Extracts of Cordyceps militaris (Ascomycetes) Lower the Levels of Plasma Glucose by Activating the Cholinergic Nerve in Streptozotocin-Induced Diabetic Rats
International Journal of Medicinal Mushrooms, Vol.15, 2013, issue 3
Chin-Hsien Chang, Chung-Yuh Tzeng, Yu-Wen Cheng, Hong-Chen Chen, Ying-I Chen, Yiu-Kay Lai, Tai-Hao Hsu, Yu-Chen Lee, Shih-Liang Chang, Chin-Chun Tsai
Characterization of the Effects of the Shiitake Culinary-Medicinal Mushroom, Lentinus edodes (Agaricomycetes), on Severe Gestational Diabetes Mellitus in Rats
International Journal of Medicinal Mushrooms, Vol.19, 2017, issue 11
Erika Leão Ajala Caetano, Leticia Favara Laurino, Angela Faustino Jozala, Carolina Alves dos Santos, Marli Gerenutti, Sara Rosicler Vieira Spim, Lucas Silva Rodrigues, Denise Grotto, Bianca Carvalho Gentil, Bianca Hessel Maschio
A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced Cancer
International Journal of Medicinal Mushrooms, Vol.4, 2002, issue 3
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease
International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Antidiabetic Properties of the Red Belt Conk Medicinal Mushroom Fomitopsis pinicola (Agaricomycetes) Extracts on Streptozotocin-Induced Diabetic Rats
International Journal of Medicinal Mushrooms, Vol.22, 2020, issue 8
Iram Abdullah, Haiying Bao, Asmaa Hussein Zaki, Muhammad Toseef Zahid, Wei Ying, Muhammad Idrees